However, most known factors have a small or modest effect on risk. The tool calculates a woman's risk of developing breast cancer within the next 5 years and within her lifetime up to age Women with a 5-year risk of 1.
The Gail Model is a statistical breast cancer risk assessment algorithm which was developed by Dr. It was developed following a huge screening study of women between 35 and 74 years of age. The Gail model has shown to be a reasonable tool for estimating breast cancer risk in white women, and other researchers have subsequently supplemented the model to provide accurate risk assessments for African American, Hispanic, and Asian women.
CARE participants included 1, women with invasive breast cancer and 1, without. SFBCS participants included 1, women with invasive breast cancer and 1, women without breast cancer. The Gail Model has been tested in large populations of white women and has been shown to provide accurate estimates of breast cancer risk.
The Breast Cancer Risk Assessment Tool allows health professionals to estimate a woman's risk of developing invasive breast cancer over the next 5 years and up to age 90 lifetime risk. The tool may underestimate risk in black women with previous biopsies and Hispanic women born outside the United States. Further studies are needed to refine and validate these models.
One of the most well-known is the Gail model, which assesses breast cancer risk based on a series of personal health questions that women and their doctors answer together. The result is a Gail score, which estimates the risk of developing invasive breast cancer in the next 5 years. The result is an estimate of the likelihood a woman will develop invasive breast cancer specifically within 10 years of her current age, as well as over the course of her lifetime.
The Gail model has been widely used and validated with conflicting results. The current study aims to evaluate the performance of different versions of the Gail model by means of systematic review and meta-analysis with trial sequential analysis TSA. Three systematic review and meta-analyses were conducted.
Calculate Risk. Risk Calculator V2 1. Does the woman have a history of breast cancer or of ductal carcinoma in situ DCISbreast augmentation, or mastectomy?
Specific Recommendations: The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer. Grade: D Specific Recommendations: The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer. Clinical Considerations:. Patient Population Under Consideration This recommendation applies to asymptomatic women aged 35 years or older without a prior diagnosis of breast cancer, ductal carcinoma in situ DCISor lobular carcinoma in situ LCIS.
Several breast cancer risk assessment tools have been developed that combine known major risk factors. Risk models can be useful in stratifying patients into risk categories to facilitate personalized screening and surveillance plans for clinical management of the patient. The Gail model is used to determine risk for purposes of advising on use of medications to reduce risk.
The BCSC Risk Calculator is an interactive tool designed by scientists that participate in the Breast Cancer Surveillance Consortium to estimate a woman's five-year risk of developing invasive breast cancer. Inthe BCSC risk calculator has been updated to include benign breast disease diagnoses and to estimate both five-year and ten-year breast cancer risk. If you are not a health professional, you are encouraged to discuss the results and your personal risk of breast cancer with your health care provider.